{"title":"Celebrating the 65th Anniversary of the Journal of Clinical Pharmacology","authors":"John van den Anker MD, PhD, FCP, FAAP","doi":"10.1002/jcph.70173","DOIUrl":null,"url":null,"abstract":"<p>It is with great pleasure that I share with you that in 2026, the American College of Clinical Pharmacology (ACCP) is celebrating the 65th anniversary of the <i>Journal of Clinical Pharmacology</i> (<i>JCP</i>). On behalf of the President of the College, the Officers, the Board of Regents, the Publications Committee, and ACCP Staff, the JCP Editorial Team will publish three special issues of the journal this year.</p><p>I would like to introduce the first two of these special issues to you in this editorial; in September, I will dedicate a separate editorial to the third. We believed that it would be important to highlight important achievements associated with JCP and therefore have dedicated one special issue to the papers that received the McKeen Cattell Award and another to celebrate the most cited papers. The latter will publish papers that have been cited 175–498 times since 2010.</p><p>With regard to the first special issue, I would like to provide additional information about Dr. McKeen Cattell, the first JCP editor.</p><p>McKeen Cattell, MD, PhD, FCP, studied as an undergraduate at Columbia and Cambridge Universities, graduating from Columbia in 1914. He subsequently received a PhD in physiology from Harvard in 1920 and graduated from Harvard Medical School before joining the Department of Physiology at Cornell University Medical College in 1924. In 1937, he became Chairman of the Department of Pharmacology, where, with the late Drs. Harry Gold (a clinician and researcher in the Department of Pharmacology at Cornell Medical College) and Nathaniel T. Kwit (a clinician at Cornell), he carried out important clinical investigations involving both animal and human subjects. These studies established a firm scientific basis for the efficacy of digitalis glycosides in congestive heart failure.</p><p>In the late 1940s, Dr. Cattell was part of a group of medical scientists who convinced the Federal Government of the importance of basic biomedical research. He later served in several key advisory roles for the National Institutes of Health and as an adviser to committees of the New York Academy of Medicine.</p><p>He served as the Editor-in-Chief of <i>The Journal of the American Society for Pharmacology and Experimental Therapeutics</i> from 1946 to 1950 and retired from Cornell as Professor of Pharmacology Emeritus in 1959. Dr. Cattell continued contributing to the field of clinical pharmacology by founding the <i>Journal of New Drugs</i> in January 1961 and serving as its Editor for the next 6 years. In 1967, <i>JCP</i> was established by Dr. Cattell, who served as its Editor for 10 years.</p><p>In collaboration with his colleagues Drs. Kwit and Gold, along with Drs. Duncan Hutcheon and Philip Reichert, Dr. Cattell became a founding father of the American College of Clinical Pharmacology, which was legally incorporated on September 11, 1969. The Articles of Incorporation list Drs. Duncan E. Hutcheon, McKeen Cattell, and Harry Gold as the initial Board of Directors.</p><p>The objectives of ACCP were listed as “to promote and advance the science of clinical pharmacology and chemotherapy in all its phases; to establish high standards of clinical investigation in this field of endeavor; to issue publications for these purposes and to engage in other appropriate educational efforts.” <i>JCP</i> became the flagship publication of ACCP and has now served the global clinical pharmacology community for over 65 years as a peer-reviewed journal.</p><p>After his passing, in 1997, in acknowledgement of his extraordinary service as the first Editor of <i>JCP</i> and co-founder of ACCP, the McKeen Cattell Memorial Award was established. It is an annual honor recognizing an outstanding paper published in <i>JCP</i>.</p><p>I sincerely hope you will enjoy these two special issues, and I wish you a most rewarding reading experience!</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13011909/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.70173","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
It is with great pleasure that I share with you that in 2026, the American College of Clinical Pharmacology (ACCP) is celebrating the 65th anniversary of the Journal of Clinical Pharmacology (JCP). On behalf of the President of the College, the Officers, the Board of Regents, the Publications Committee, and ACCP Staff, the JCP Editorial Team will publish three special issues of the journal this year.
I would like to introduce the first two of these special issues to you in this editorial; in September, I will dedicate a separate editorial to the third. We believed that it would be important to highlight important achievements associated with JCP and therefore have dedicated one special issue to the papers that received the McKeen Cattell Award and another to celebrate the most cited papers. The latter will publish papers that have been cited 175–498 times since 2010.
With regard to the first special issue, I would like to provide additional information about Dr. McKeen Cattell, the first JCP editor.
McKeen Cattell, MD, PhD, FCP, studied as an undergraduate at Columbia and Cambridge Universities, graduating from Columbia in 1914. He subsequently received a PhD in physiology from Harvard in 1920 and graduated from Harvard Medical School before joining the Department of Physiology at Cornell University Medical College in 1924. In 1937, he became Chairman of the Department of Pharmacology, where, with the late Drs. Harry Gold (a clinician and researcher in the Department of Pharmacology at Cornell Medical College) and Nathaniel T. Kwit (a clinician at Cornell), he carried out important clinical investigations involving both animal and human subjects. These studies established a firm scientific basis for the efficacy of digitalis glycosides in congestive heart failure.
In the late 1940s, Dr. Cattell was part of a group of medical scientists who convinced the Federal Government of the importance of basic biomedical research. He later served in several key advisory roles for the National Institutes of Health and as an adviser to committees of the New York Academy of Medicine.
He served as the Editor-in-Chief of The Journal of the American Society for Pharmacology and Experimental Therapeutics from 1946 to 1950 and retired from Cornell as Professor of Pharmacology Emeritus in 1959. Dr. Cattell continued contributing to the field of clinical pharmacology by founding the Journal of New Drugs in January 1961 and serving as its Editor for the next 6 years. In 1967, JCP was established by Dr. Cattell, who served as its Editor for 10 years.
In collaboration with his colleagues Drs. Kwit and Gold, along with Drs. Duncan Hutcheon and Philip Reichert, Dr. Cattell became a founding father of the American College of Clinical Pharmacology, which was legally incorporated on September 11, 1969. The Articles of Incorporation list Drs. Duncan E. Hutcheon, McKeen Cattell, and Harry Gold as the initial Board of Directors.
The objectives of ACCP were listed as “to promote and advance the science of clinical pharmacology and chemotherapy in all its phases; to establish high standards of clinical investigation in this field of endeavor; to issue publications for these purposes and to engage in other appropriate educational efforts.” JCP became the flagship publication of ACCP and has now served the global clinical pharmacology community for over 65 years as a peer-reviewed journal.
After his passing, in 1997, in acknowledgement of his extraordinary service as the first Editor of JCP and co-founder of ACCP, the McKeen Cattell Memorial Award was established. It is an annual honor recognizing an outstanding paper published in JCP.
I sincerely hope you will enjoy these two special issues, and I wish you a most rewarding reading experience!
我很高兴地告诉大家,在2026年,美国临床药理学学院(ACCP)将庆祝《临床药理学杂志》(JCP)创刊65周年。JCP编辑团队将代表学院校长、管理人员、校董会、出版委员会和ACCP员工出版今年的三期特刊。我想在这篇社论中向你们介绍前两个特别问题;9月,我将专门为第三个问题写一篇社论。我们认为,突出与JCP相关的重要成就是很重要的,因此,我们专门为获得McKeen Cattell奖的论文制作了一期特刊,并为被引用最多的论文制作了另一期特刊。后者将从2010年开始发表被引175 ~ 498次的论文。关于第一期特刊,我想提供关于第一任JCP编辑McKeen Cattell博士的额外信息。McKeen Cattell,医学博士,FCP,本科就读于哥伦比亚大学和剑桥大学,1914年从哥伦比亚大学毕业。随后,他于1920年获得哈佛大学生理学博士学位,毕业于哈佛医学院,并于1924年加入康奈尔大学医学院生理学系。1937年,他成为药学系的主席。Harry Gold(康奈尔医学院药学系的临床医生和研究员)和Nathaniel T. Kwit(康奈尔医学院的临床医生),他进行了涉及动物和人类受试者的重要临床研究。这些研究为洋地黄苷治疗充血性心力衰竭的疗效奠定了坚实的科学基础。在20世纪40年代末,卡特尔博士是一群医学科学家中的一员,他们使联邦政府相信基础生物医学研究的重要性。后来,他在美国国立卫生研究院(National Institutes of Health)担任几个重要的顾问职务,并担任纽约医学院(New York Academy of Medicine)委员会的顾问。1946年至1950年,他担任the Journal of the American Society for Pharmacology and Experimental Therapeutics的主编,1959年从康奈尔大学药理学名誉教授退休。他在1961年1月创办了《新药物杂志》,并在接下来的6年里担任其编辑,继续为临床药理学领域做出贡献。1967年,卡特博士创办了JCP,他担任了10年的编辑。在与同事的合作中。Kwit和Gold以及dr。Duncan Hutcheon和Philip Reichert, Cattell博士是美国临床药理学学院的创始人之一,该学院于1969年9月11日合法成立。公司章程列出了博士。Duncan E. Hutcheon, McKeen Cattell和Harry Gold担任最初的董事会成员。ACCP的目标是“促进和推进临床药理学和化疗科学的各个阶段;在这一领域努力建立高标准的临床研究;为此目的发行出版物,并从事其他适当的教育工作。”JCP成为ACCP的旗舰出版物,现在已经为全球临床药理学社区提供了超过65年的同行评审期刊。1997年他去世后,为表彰他作为《JCP》首任主编和ACCP联合创始人的杰出贡献,设立了麦基恩·卡特尔纪念奖。这是一项年度荣誉,旨在表彰在JCP上发表的杰出论文。我真诚地希望你会喜欢这两期特刊,并祝你有一个最有益的阅读体验!